Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (Alzheimer's Research & Therapy, (2023), 15, 1, (39), 10.1186/s13195-023-01169-x)

Bruno Dubois; Jesús López‑Arrieta; Stanley Lipschitz; Triantafyllos Doskas; Luiza Spiru; Svitlana Moroz; Olena Venger; Patrick Vermersch; Alain Moussy; Colin D. Mansfield; Olivier Hermine; Magda Tsolaki

ArticleOPEN ACCESS

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (Alzheimer's Research & Therapy, (2023), 15, 1, (39), 10.1186/s13195-023-01169-x)

Alzheimer's Research and Therapy

DOI: 10.1186/s13195-023-01230-9

1Citations

8Readers

Abstract

Following publication of the original article [1], the authors identified an error in the author name of Triantafyllos Doskas. The given name and family name were reversed. The incorrect author name is: Doskas Triantafyllos The correct author name is: Triantafyllos Doskas The author group has been updated above and the original article [1] has been corrected.

Cite

CITATION STYLE

APA

Dubois, B., López‑Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., … Tsolaki, M. (2023, December 1). Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (Alzheimer’s Research & Therapy, (2023), 15, 1, (39), 10.1186/s13195-023-01169-x). Alzheimer’s Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/s13195-023-01230-9

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (Alzheimer's Research & Therapy, (2023), 15, 1, (39), 10.1186/s13195-023-01169-x)

Abstract

Cite

Register to see more suggestions